MX2024007894A - Fitusirán para su uso para mejorar el resultado comunicado por el paciente en pacientes con hemofilia. - Google Patents
Fitusirán para su uso para mejorar el resultado comunicado por el paciente en pacientes con hemofilia.Info
- Publication number
- MX2024007894A MX2024007894A MX2024007894A MX2024007894A MX2024007894A MX 2024007894 A MX2024007894 A MX 2024007894A MX 2024007894 A MX2024007894 A MX 2024007894A MX 2024007894 A MX2024007894 A MX 2024007894A MX 2024007894 A MX2024007894 A MX 2024007894A
- Authority
- MX
- Mexico
- Prior art keywords
- hemophilia
- patients
- improve patient
- fitusiran
- patient reported
- Prior art date
Links
- 208000009292 Hemophilia A Diseases 0.000 title abstract 2
- 208000031220 Hemophilia Diseases 0.000 title 1
- RUPXJRIDSUCQAN-PQNNUJSWSA-N N-[1,3-bis[3-[3-[5-[(2R,3R,4R,5R,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypentanoylamino]propylamino]-3-oxopropoxy]-2-[[3-[3-[5-[(2R,3R,4R,5R,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypentanoylamino]propylamino]-3-oxopropoxy]methyl]propan-2-yl]-12-[(2R,4R)-4-hydroxy-2-methylpyrrolidin-1-yl]-12-oxododecanamide Chemical compound C[C@@H]1C[C@@H](O)CN1C(=O)CCCCCCCCCCC(=O)NC(COCCC(=O)NCCCNC(=O)CCCCO[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1NC(C)=O)(COCCC(=O)NCCCNC(=O)CCCCO[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1NC(C)=O)COCCC(=O)NCCCNC(=O)CCCCO[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1NC(C)=O RUPXJRIDSUCQAN-PQNNUJSWSA-N 0.000 title 1
- 229950002735 fitusiran Drugs 0.000 title 1
- 102100022641 Coagulation factor IX Human genes 0.000 abstract 1
- 102100026735 Coagulation factor VIII Human genes 0.000 abstract 1
- 201000003542 Factor VIII deficiency Diseases 0.000 abstract 1
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 abstract 1
- 108091034117 Oligonucleotide Proteins 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 208000009429 hemophilia B Diseases 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163293070P | 2021-12-22 | 2021-12-22 | |
| US202263305550P | 2022-02-01 | 2022-02-01 | |
| US202263335535P | 2022-04-27 | 2022-04-27 | |
| US202263359717P | 2022-07-08 | 2022-07-08 | |
| US202263382223P | 2022-11-03 | 2022-11-03 | |
| US202263386489P | 2022-12-07 | 2022-12-07 | |
| PCT/US2022/082213 WO2023122713A1 (en) | 2021-12-22 | 2022-12-22 | Fitusiran for use in improving patient-reported outcome in hemophilia patients |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024007894A true MX2024007894A (es) | 2024-08-20 |
Family
ID=85227438
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024007894A MX2024007894A (es) | 2021-12-22 | 2022-12-22 | Fitusirán para su uso para mejorar el resultado comunicado por el paciente en pacientes con hemofilia. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250064842A1 (https=) |
| EP (1) | EP4452280A1 (https=) |
| JP (1) | JP2025500412A (https=) |
| KR (1) | KR20240138572A (https=) |
| AU (1) | AU2022419588A1 (https=) |
| CA (1) | CA3243297A1 (https=) |
| IL (1) | IL313677A (https=) |
| MX (1) | MX2024007894A (https=) |
| TW (1) | TW202342065A (https=) |
| WO (1) | WO2023122713A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025171279A1 (en) * | 2024-02-09 | 2025-08-14 | Genzyme Corporation | Treatment of hemophilia with fitusiran |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9127274B2 (en) | 2012-04-26 | 2015-09-08 | Alnylam Pharmaceuticals, Inc. | Serpinc1 iRNA compositions and methods of use thereof |
| KR20180095843A (ko) | 2015-12-07 | 2018-08-28 | 젠자임 코포레이션 | Serpinc1-연관 장애의 치료를 위한 방법 및 조성물 |
| TW202434265A (zh) | 2017-07-10 | 2024-09-01 | 美商健贊公司 | 於患有血友病之個體中治療出血事件之方法及組成物 |
| WO2022120291A1 (en) * | 2020-12-06 | 2022-06-09 | Genzyme Corporation | Treatment of hemophilia with fitusiran |
-
2022
- 2022-12-21 TW TW111149131A patent/TW202342065A/zh unknown
- 2022-12-22 KR KR1020247024462A patent/KR20240138572A/ko active Pending
- 2022-12-22 EP EP22857063.6A patent/EP4452280A1/en active Pending
- 2022-12-22 AU AU2022419588A patent/AU2022419588A1/en active Pending
- 2022-12-22 MX MX2024007894A patent/MX2024007894A/es unknown
- 2022-12-22 CA CA3243297A patent/CA3243297A1/en active Pending
- 2022-12-22 US US18/723,352 patent/US20250064842A1/en active Pending
- 2022-12-22 WO PCT/US2022/082213 patent/WO2023122713A1/en not_active Ceased
- 2022-12-22 JP JP2024537896A patent/JP2025500412A/ja active Pending
- 2022-12-22 IL IL313677A patent/IL313677A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW202342065A (zh) | 2023-11-01 |
| JP2025500412A (ja) | 2025-01-09 |
| AU2022419588A1 (en) | 2024-08-01 |
| US20250064842A1 (en) | 2025-02-27 |
| EP4452280A1 (en) | 2024-10-30 |
| WO2023122713A1 (en) | 2023-06-29 |
| KR20240138572A (ko) | 2024-09-20 |
| IL313677A (en) | 2024-08-01 |
| CA3243297A1 (en) | 2023-06-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2021001575A1 (es) | Pirazolopirimidinas sustituidas y purinas sustituidas y su uso como inhibidores de proteasa procesadora específica de ubiquitina 1 (usp1) | |
| MX2021011209A (es) | Novedosos inhibidores de molécula pequeña de factores de transcripción tead. | |
| MX2022012992A (es) | Inhibidores de kif18a para el tratamiento de enfermedades neoplasicas. | |
| CO2020015758A2 (es) | Compuestos de purinona y su uso en el tratamiento del cáncer | |
| CO2019007810A2 (es) | Compuestos de amino-triazolopiridina y su uso en el tratamiento del cáncer | |
| CO2017013432A2 (es) | Compuestos de indazol-fenil-fenoxi-enamida y sus variaciones | |
| CO6960552A2 (es) | Compuestos de (hetero)arilciclopropilamina como inhibidores de lsd1 | |
| NI201500123A (es) | Inhibidores quinazolínicos de formas mutadas activantes del receptor del factor de crecimiento epidérmico | |
| CR20170477A (es) | Terapia de combinacin del receptor del factor de crecimiento de fibroblastos (fgfr)/muerte programada 1 (pd 1) para el tratamiento del cncer | |
| MX2020007060A (es) | Compuestos, composiciones y metodos para tratar enfermedades que involucren tejidos con enfermedades acidas o hipoxicas. | |
| MX2017014584A (es) | Inhibidores heterociclicos de erk1 y erk2 y su uso en el tratamiento del cancer. | |
| MX2014001218A (es) | Tratamiento de cancer de mama. | |
| MX338447B (es) | Tratamiento para diabetes en pacientes inapropirados para terapia con metformina. | |
| PA8637201A1 (es) | Difenilimidazopirimidina e-imidazol aminas como inhibidores de la b-secretasa | |
| CO6351742A2 (es) | Compuestos organicos para la cicatrizacion de heridas | |
| AR077125A1 (es) | Combinaciones farmaceuticas utiles para tratar el vhc | |
| CL2023000943A1 (es) | Formas cristalinas de un compuesto farmacéutico. | |
| MX2022001004A (es) | Inhibidores de enzimas. | |
| CO2023000703A2 (es) | Métodos de tratamiento del cáncer mediante derivados heteroaril-bifenil-amida | |
| CO2025003263A2 (es) | Inhibidores de kif18a y usos de estos | |
| DOP2019000100A (es) | Derivados de naftiridinona y su uso en el tratamiento de la arritmia | |
| CO2024014485A2 (es) | Compuestos heterociclicos moduladores de bcl6 como degradadores dirigidos por ligando | |
| MX386293B (es) | Compuestos de aminoindano y su uso en el tratamiento del dolor. | |
| MX2023000164A (es) | Métodos y composiciones para tratar la hemofilia. | |
| CO2024007220A2 (es) | Compuestos que contienen heteroátomos y usos de estos |